21 May 2010
Mumbai, India
Ranbaxy Laboratories has said that its European unit is recalling select batches of three products, including anti–depressants, to add mandatory safety warnings.
Though the move is unlikely to have a financial impact, it will only add to the woes of the generic major, which is under the scanner of the US drug authorities for not adhering to certain manufacturing practices.
Though Ranbaxy has clarified that there were no ‘product quality concerns’, two products were being recalled from Britain and Denmark and one from Ireland. The company refused to name the products.
"The recall is being carried out as patient information leaflets need to be updated to include safety warnings initiated by the European Medicines Agency,’’ the company said in a statement.
Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.
